Could cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013 Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteIn Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis Faith Borgan, Heikki Laurikainen, Mattia Veronese, Tiago Reis Marques, Merja Haaparanta-Solin, Olof Solin, Tarik Dahoun, Maria Rogdaki, Raimo KR Salokangas, Max Karukivi, Marta Di Forti, Federico Turkheimer, Jarmo Hietala, Oliver Howes for the METSY Group JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.1427 IMPORTANCE Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown. OBJECTIVE To investigate CB1R availability in first-episode psychosis (FEP) without the [...]
Lire la suiteCannabidiol as a potential treatment for psychosis Cathy Davies and Sagnik Bhattacharyya Therapeutic Advances in Psychopharmacology, 2019, Vol. 9, 1–16 https://doi.org/10.1177%2F2045125319881916 Abstract : Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of [...]
Lire la suiteCannabidiol as a potential treatment for psychosis C.D. Schubart, I.E.C. Sommer, P. Fusar-Poli, L. de Witte, R.S. Kahn, M.P.M. Boks European Neuropsychopharmacology, 2014, 24 ,(1), 51–64. http://dx.doi.org/10.1016/j.euroneuro.2013.11.002 Abstract Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if [...]
Lire la suiteRole of the Endocannabinoid System in the Pathophysiology of Schizophrenia M. Fakhoury Molecular Neurobiology, 2017, 54, (1), 768-778. doi: 10.1007/s12035-016-9697-5 ABSTRACT : The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the [...]
Lire la suiteTherapeutic potential of cannabinoids in schizophrenia, KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. Recent Patents on CNS Drug Discovery, 2014, 9, (1), 13-25. Doi : 10.2174/1574889809666140307115532 Abstract Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydro-cannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoyl-glycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during [...]
Lire la suiteCannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suiteA systematic review of the antipsychotic properties of cannabidiol in humans T.A. Iseger, M.G. Bossong Schizophrenia Research, 2015, 162, (1-3), 153-161 doi: 10.1016/j.schres.2015.01.033 Abstract Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) [...]
Lire la suiteThe Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis Britta Hahn Schizophrenia Bulletin, 2018, vol. 44, no. 1, 46–53 doi:10.1093/schbul/sbx105 A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to Δ9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective [...]
Lire la suite